Crome/Cobalt Respiration Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Alyssa Pieper
- Phone Number: 763-505-0054
- Email: alyssa.k.pieper@medtronic.com
Study Locations
-
-
Connecticut
-
Hartford, Connecticut, United States, 06102
- Hartford Hospital
-
-
Minnesota
-
Saint Cloud, Minnesota, United States, 56303-1900
- CentraCare Heart & Vascular Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73135
- South Oklahoma Heart Research
-
-
Texas
-
Austin, Texas, United States, 78705-1852
- Texas Cardiac Arrhythmia Research Foundation
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subject has an active CromeTM or CobaltTM ICD or CRT-D MRI SureScanTM system which has been implanted for at least 30 days and which has not yet reached the Recommended Replacement Time (RRT)
Subject is implanted with one of the following models of a true bipolar right ventricular lead manufactured by Medtronic:
- Model 6946M
- Model 6947
- Model 6947M
- Model 6935
- Model 6935M
- Subject is ≥ 18 years of age
- Subject (or subject's legally authorized representative) is willing and able to provide written informed consent
- Subject is willing and able to comply with study procedures
Exclusion Criteria:
- Subject has existing condition that necessitates the use of supplemental oxygen
- Subject has active acute respiratory infection or respiratory disorder that may affect ability to perform breathing or exercise activities, as assessed by the investigator
- Any concomitant condition that might endanger the subject through participation in the study or interfere with study procedures, as assessed by the investigator
- Subject has an active or suspected lead integrity issue, in the opinion of the investigator
- Subject is enrolled in another study that could confound the results of this study
- Subject has NYHA Class IV heart failure
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
All Enrolled Subjects
In-clinic Testing Visit: All enrolled subjects will have a Holter recorder, capnography monitor and SpO2 sensor applied and will undergo various breathing/exercise activities.
Subjects will go home connected to the Holter recorder for 24 hours for collection of ambulatory data.
|
The Sensor Research Holter Mode feature within the Crome and Cobalt ICD and CRT-D devices will be enabled for a short period of time at the In-clinic Testing Visit to allow for desired data collection.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Daily Capnography Respiration Rate
Time Frame: During In-clinic Testing Visit, an average of 2 hours
|
Daily respiration rates will be calculated using a series of paired device-derived respiration rates and capnography waveform-derived respiration rates, where the capnography respiration rate will be the source of truth.
The differences in these daily respiration rates will be evaluated to determine whether the daily device-derived respiration rate accuracy is acceptable (i.e., consistently within +/- 3 breaths per minute of the true respiration rate).
|
During In-clinic Testing Visit, an average of 2 hours
|
|
Daily Device-derived Respiration Rate
Time Frame: During In-clinic Testing Visit, an average of 2 hours
|
Daily respiration rate determined by the Crome and Cobalt ICD and CRT-D devices.
|
During In-clinic Testing Visit, an average of 2 hours
|
|
Difference in Respiration Rate
Time Frame: During In-clinic Testing Visit, an average of 2 hours
|
Difference between the daily respiration rate determined using capnography and the daily respiration rate determined by the Crome and Cobalt ICD and CRT-D devices.
|
During In-clinic Testing Visit, an average of 2 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MDT22030
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.